Literature DB >> 19747356

Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis.

Mohammed A A M Nouh1, Naoto Kuroda, Motoki Yamashita, Yushi Hayashida, Toshifumi Yano, Jun Minakuchi, Susumu Taniguchi, Isaku Nomura, Masashi Inui, Mikio Sugimoto, Yoshiyuki Kakehi.   

Abstract

OBJECTIVE: To evaluate the clinical outcomes and histological types of renal cell carcinoma (RCC) arising in patients with end-stage renal disease (ESRD), and to analyse the relationship of histopathological features with the duration of dialysis. PATIENTS AND METHODS: Clinical characteristics and outcomes of 34 patients who had a radical nephrectomy for RCC arising in ESRD between November 1994 and June 2008 were investigated. Archive paraffin-embedded tissue specimens obtained from 27 patients were histochemically and immunohistochemically analysed to determine the histopathological type.
RESULTS: There was one death from cancer and one patient with local progression within a median observation period of 29.5 months. Acquired cystic disease (ACD)-associated RCC, clear cell-papillary RCC, mucinous tubular and spindle-cell carcinoma, and Xp11.2 translocation/TFE3 gene fusion were identified in eight, two, three and one patient, respectively. Conventional clear-cell RCC was the predominant histological type (nine of 15) in patients with a duration of dialysis of <10 years, while ACD-associated RCC was predominant (seven of 12) in those with dialysis for > or =10 years. Sarcomatoid foci were identified in three patients with dialysis for > or =10 years. Papillary adenoma was microscopically identified as a satellite tumour in 10 patients.
CONCLUSION: The spectrum of histological types of RCCs arising in ESRD is distinct from that of sporadic RCCs. Patients with a longer duration of dialysis should have particular attention for progression and metastasis. Immunohistochemical profiling is efficient in the histological classification of RCCs arising in ESRD, although knowledge about genetic changes remains to be accumulated.

Entities:  

Mesh:

Year:  2009        PMID: 19747356     DOI: 10.1111/j.1464-410X.2009.08817.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  21 in total

1.  Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.

Authors:  Toru Inoue; Keiko Matsuura; Taichiro Yoshimoto; Lam Tung Nguyen; Yoshiyuki Tsukamoto; Chisato Nakada; Naoki Hijiya; Takahiro Narimatsu; Takeo Nomura; Fuminori Sato; Yoji Nagashima; Kenji Kashima; Shingo Hatakeyama; Chikara Ohyama; Kazuyuki Numakura; Tomonori Habuchi; Masayuki Nakagawa; Masao Seto; Hiromitsu Mimata; Masatsugu Moriyama
Journal:  Cancer Sci       Date:  2012-01-20       Impact factor: 6.716

Review 2.  Risk of chronic kidney disease after cancer nephrectomy.

Authors:  Lin Li; Wei Ling Lau; Connie M Rhee; Kevin Harley; Csaba P Kovesdy; John J Sim; Steve Jacobsen; Anthony Chang; Jaime Landman; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

3.  Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma.

Authors:  Fumiyoshi Fushimi; Kenichi Taguchi; Hiroto Izumi; Kimitoshi Kohno; Michihiko Kuwano; Mayumi Ono; Yutaka Nakashima; Tetsuro Takesue; Seiji Naito; Yoshinao Oda
Journal:  Virchows Arch       Date:  2013-08-02       Impact factor: 4.064

Review 4.  Clear cell papillary renal cell carcinoma: a review.

Authors:  Naoto Kuroda; Chisato Ohe; Fumi Kawakami; Shuji Mikami; Mitsuko Furuya; Keiko Matsuura; Masatsugu Moriyama; Yoji Nagashima; Ming Zhou; Fredrik Petersson; José I López; Ondrej Hes; Michal Michal; Mahul B Amin
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

5.  Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.

Authors:  Kenji Omae; Tsunenori Kondo; Takafumi Kennoki; Toshio Takagi; Junpei Iizuka; Hirohito Kobayashi; Yasunobu Hashimoto; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2015-07-11       Impact factor: 3.402

6.  Imaging of acquired cystic disease-associated renal cell carcinoma by contrast-enhanced ultrasonography with perflubutane microbubbles and positron emission tomography-computed tomography.

Authors:  Isao Ishikawa; Kyoko Morita; Satoshi Hayama; Tetsuya Nakazawa; Ichiro Araki; Kotaro Higashi; Katsuhito Miyazawa; Koji Suzuki; Takayuki Nojima
Journal:  Clin Exp Nephrol       Date:  2010-09-09       Impact factor: 2.801

7.  Acquired cystic disease-associated renal cell carcinoma: further characterization of the morphologic and immunopathologic features.

Authors:  Soomin Ahn; Ghee Young Kwon; Yong Mee Cho; Sun-Young Jun; Chan Choi; Hyun-Jung Kim; Yong Wook Park; Weon Seo Park; Jung Won Shim
Journal:  Med Mol Morphol       Date:  2013-03-08       Impact factor: 2.309

Review 8.  The epidemiology and risk factors for renal cancer.

Authors:  Tahir Qayyum; Grenville Oades; Paul Horgan; Michael Aitchison; Joanne Edwards
Journal:  Curr Urol       Date:  2013-02-08

9.  A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.

Authors:  Aiko Kurisaki-Arakawa; Tsuyoshi Saito; Michiko Takahashi; Keiko Mitani; Yuki Fukumura; Yoji Nagashima; Pedrum Argani; Takashi Yao
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

Review 10.  Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas.

Authors:  Qiu Rao; Qiu-Yuan Xia; Liang Cheng; Xiao-Jun Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.